Fulton Breakefield Broenniman LLC Makes New Investment in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Fulton Breakefield Broenniman LLC bought a new stake in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 23,579 shares of the company’s stock, valued at approximately $215,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its stake in shares of Phathom Pharmaceuticals by 355.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,626 shares of the company’s stock valued at $60,000 after buying an additional 5,171 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Phathom Pharmaceuticals by 371.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,429 shares of the company’s stock worth $87,000 after purchasing an additional 6,641 shares during the last quarter. DAVENPORT & Co LLC acquired a new position in Phathom Pharmaceuticals in the fourth quarter valued at approximately $91,000. Public Employees Retirement System of Ohio acquired a new position in Phathom Pharmaceuticals in the third quarter valued at approximately $92,000. Finally, Principal Financial Group Inc. lifted its holdings in Phathom Pharmaceuticals by 11.9% in the third quarter. Principal Financial Group Inc. now owns 11,801 shares of the company’s stock valued at $122,000 after acquiring an additional 1,259 shares during the last quarter. Institutional investors own 99.01% of the company’s stock.

Insider Transactions at Phathom Pharmaceuticals

In related news, CFO Molly Henderson sold 3,435 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $11.10, for a total transaction of $38,128.50. Following the sale, the chief financial officer now owns 95,263 shares in the company, valued at $1,057,419.30. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CFO Molly Henderson sold 3,435 shares of the firm’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $11.10, for a total value of $38,128.50. Following the transaction, the chief financial officer now owns 95,263 shares of the company’s stock, valued at approximately $1,057,419.30. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Terrie Curran sold 16,851 shares of the firm’s stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $9.11, for a total transaction of $153,512.61. Following the completion of the transaction, the insider now directly owns 410,784 shares in the company, valued at approximately $3,742,242.24. The disclosure for this sale can be found here. Corporate insiders own 24.10% of the company’s stock.

Phathom Pharmaceuticals Trading Up 0.9 %

NASDAQ PHAT traded up $0.08 during trading hours on Friday, hitting $9.18. 370,890 shares of the stock were exchanged, compared to its average volume of 725,758. Phathom Pharmaceuticals, Inc. has a 12-month low of $6.07 and a 12-month high of $17.02. The stock has a 50-day moving average of $9.85 and a 200 day moving average of $8.70.

Phathom Pharmaceuticals (NASDAQ:PHAT) last issued its earnings results on Thursday, March 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.12. The company had revenue of $0.68 million during the quarter, compared to analysts’ expectations of $0.93 million. During the same period last year, the business posted ($1.33) earnings per share. Equities research analysts expect that Phathom Pharmaceuticals, Inc. will post -4.22 EPS for the current year.

Analysts Set New Price Targets

Separately, Needham & Company LLC reissued a “buy” rating and issued a $26.00 target price on shares of Phathom Pharmaceuticals in a research report on Friday.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.